G

GH Research PLC
NASDAQ:GHRS

Watchlist Manager
GH Research PLC
NASDAQ:GHRS
Watchlist
Price: 9.27 USD -3.64% Market Closed
Market Cap: 482.3m USD
Have any thoughts about
GH Research PLC?
Write Note

GH Research PLC
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GH Research PLC
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
G
GH Research PLC
NASDAQ:GHRS
Net Issuance of Debt
-$219k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Net Issuance of Debt
$666.1m
CAGR 3-Years
N/A
CAGR 5-Years
42%
CAGR 10-Years
-6%
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Net Issuance of Debt
$374.8m
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
-8%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Net Issuance of Debt
-$21.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
3%
Cosmo Pharmaceuticals NV
SIX:COPN
Net Issuance of Debt
-€176.1m
CAGR 3-Years
-226%
CAGR 5-Years
N/A
CAGR 10-Years
-58%
Ovoca Bio PLC
LSE:OVB
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GH Research PLC
Glance View

Market Cap
482.3m USD
Industry
Pharmaceuticals

GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

GHRS Intrinsic Value
4.27 USD
Overvaluation 54%
Intrinsic Value
Price
G

See Also

What is GH Research PLC's Net Issuance of Debt?
Net Issuance of Debt
-219k USD

Based on the financial report for Dec 31, 2023, GH Research PLC's Net Issuance of Debt amounts to -219k USD.

Back to Top